You are here

Ciclopirox Olamine Cream Approved

HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 14, 2005-- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO - News) reported today that Taro Pharmaceuticals U.S.A., Inc. has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Ciclopirox Olamine Cream USP, 0.77% ("ciclopirox cream").

Taro's ciclopirox cream is a prescription pharmaceutical product used for the treatment of fungal infections of the skin. The Taro product is bioequivalent to Medicis Pharmaceutical Corp.'s Loprox® Topical Cream. According to industry sources, ciclopirox cream products had U.S. sales of approximately $32.5 million in 2004.

Source: Taro Pharmaceutical Industries, Inc.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key